Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 2,400 shares at $5.00 ($12K) on 2024-11-25, disclosed to the SEC on 2024-11-26.
Scheduled sale ($12k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.00 | 1,600 | $8K | 66.7% |
| 2 | $5.00 | 800 | $4K | 33.3% |
| Total | $5.00 avg | 2,400 | $12K | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |